KMX vs STRO · P/E 19, rev $26.35B vs rev $62.0M
CarMax Inc (KMX) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
CarMax Inc (KMX) is a auto & truck dealerships company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported KMX revenue for 2025-02-28 was $26.35B. Net income was $500.6M. Revenue was down 0.7% from 2024-02-29 to 2025-02-28. KMX currently screens at market cap $10.26B and trailing P/E 18.9.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
KMX currently screens at market cap $10.26B and trailing P/E 18.9. STRO currently screens at market cap $470.8M.
Not investment advice. Open the KMX and STRO stock pages for the full models.
Not investment advice.